• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate (suspended)

Entecavir and tenofovir disoproxil fumarate for the treatment of chronic hepatitis B in adults with decompensated liver disease (suspended)

Status:	Suspended
Expected date of issue:	TBC
Wave:	21
Process:	MTA
Topic area: Digestive system Infectious diseases

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	TBC
Technical Lead:	TBC
Communications manager:	TBC
Project manager:	TBC

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	TBC
1st appraisal committee meeting:	TBC
2nd appraisal committee meeting:	TBC

Top

 

Consultees and commentators

To be confirmed

Top

 

Project history

Date   Update     8 March 2011 Following the additional draft scope consultation, further discussions with the Department of Health and noting the overlap between the Technology Appraisal and the recently referred Clinical Guideline; The diagnosis and management of hepatitis B in children, adolescents and adults, it has been decided that the Technology Appraisal will be suspended until the outcome of the scoping process for the Clinical Guideline is known.   Please see http://guidance.nice.org.uk/CG/Wave25/7 for more information regarding the Clinical Guideline of ‘The diagnosis and management of hepatitis B in children, adolescents and adults’.   6 May 2010   Please note that this appraisal is now expected to start in approximately early December 2010. The deadline for submissions is expected in approximately late March 2011.

Top

 

Key documents

Provisional matrix for consultation - September 2010 15 September 2010 Draft scope for consultation - September 2010 15 September 2010

This page was last updated: 27 April 2011